GlobeNewswire

Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress

Share

Press Release

17 September 2020

Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress

Immunicum AB (publ: IMMU.ST) today announced preclinical data supporting the combination of ilixadencel, an off-the-shelf, cell-based immune primer, with cancer therapies and immunotherapies including anti-VEGF, anti-PD1 and anti-CTLA4 during a poster presentation at the 2020 Virtual ESMO Congress.

Earlier communicated results from preclinical studies in mice demonstrated that animals treated with the combination of ilixadencel and anti-CTLA4 showed a stronger anti-tumor response as compared to animals treated with anti-PD1 and anti-CTLA4, a potent and marketed combination of checkpoint inhibitors. Following the completion of additional experiments, Immunicum observed that ilixadencel, when combined with, anti-VEGF, anti-CTLA4 or anti-CTLA4 and anti-PD1, enabled Complete Responses in a colon carcinoma tumor model (CT26) in mice.

“Our preclinical studies are focused on evaluating ilixadencel in combination with different cancer therapies to identify the most synergistic combinations to explore in clinical trials and gain further insight on ilixadencel’s mechanism of action. The preclinical results on tumor response and survival with ilixadencel in combination with anti-VEGF antibodies are further in line with the outcome of the MERECA trial in which ilixadencel was tested in kidney cancer patients in combination with the VEGF inhibitor, sunitinib, indicating that the anti-tumor effect seen in the used tumor model has clinical relevance. From these additional preclinical experiments, we also see strong mechanistic and efficacy rationale of investigating novel combinations. Overall, as we strengthen our data package, we look forward to providing updates on the next steps for our clinical development program,” commented Alex Karlsson-Parra, Chief Scientific Officer of Immunicum.  

In the experiments, groups of 5 to 10 mice with established tumors (approximately 100 mm3) were administered either monotherapy, ilixadencel in combination with anti-VEGF, anti-PD1 or anti-CTLA4 or the triple combination of ilixadencel, anti-PD1 and anti-CTLA4. One control group was treated with anti-PD1 combined with anti-CTLA4. Results from two experiments demonstrated that 50-70% of the treated mice in the ilixadencel/anti-CTLA4 groups showed a Complete Response and were found to be protected from tumor regrowth upon subsequent tumor rechallenge. An additional experiment further demonstrated that the addition of ilixadencel to anti-PD1 and anti-CTLA4 resulted in a Complete Response in 60% of the treated mice, as compared to 10% for the anti-PD1/anti-CTLA4 control group. In the ilixadencel/anti-VEGF group, tumor progression was delayed and resulted in a Complete Response in 10% of the treated mice, as compared to 0% for the anti-VEGF control group. Immune cell depletion experiments were conducted in the ilixadencel combination with anti-CTLA4, demonstrating that the effects are primarily driven by CD8+ T cells, with substantial involvement of both CD4+ T cells and NK cells, thus in line with ilixadencel’s anticipated mechanism of action.

The poster presentation is available on Immunicum’s corporate website.

About ilixadencel
Ilixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Injection of these cells in the patient’s tumor generates an inflammatory response which in turns leads to tumor-specific activation of the patient’s cytotoxic T cells. To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST) and in combination with several standard-of-care cancer therapies such as the tyrosine kinase inhibitors Sutent® (sunitinib) and Stivarga® (regorafenib), and the checkpoint inhibitor Keytruda® (pembrolizumab). Ilixadencel has consistently maintained a positive safety and tolerability profile and demonstrated initial signs of efficacy as seen in the randomized Phase II MERECA trial. Ilixadencel is currently moving towards late-stage clinical development.

For more information, please contact:

Alex Karlsson-Parra, CSO, Immunicum
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

Sijme Zeilemaker, COO, Immunicum
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

INVESTOR RELATIONS

Jonas Rodny
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.com

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Touax: Success of the partial buyback of the Undated Deeply Subordinated Bond27.11.2020 17:45:00 CETPress release

PRESS RELEASE Paris, November 27, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Success of the partial buyback of the Undated Deeply Subordinated Bond Touax SCA announces today that it has bought back and canceled part of the Undated Deeply Subordinated Bond issued in August 2013, November 2013 and May 2014, for a nominal amount of 24.2 million euros. The outstanding amount of the bonds stands at 26.6 million euros. This operation will enable to optimize the capital structure of the Group and to lower the related costs. Fabrice and Raphaël Walewski, managing partners of Touax Group commented: “The strategic refocusing initiated since 2018 around the long-term rental business of environmentally-friendly transport equipment has allowed a return to growth and profit over the first half of 2020. The capital increase of Touax Rail for 81.9 million euros achieved at the end of September 2020 significantly strengthened the capital of the Rail division and t

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS27.11.2020 16:20:00 CETPress release

Anbudsförfarande kommuner och regioner, 2020-12-01BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2025 The following issuers are accepted for delivery: Göteborgs Stad Jönköpings Kommun Malmö Stad Nacka Kommun Region Skåne Stockholms Stad Region Stockholm Vellinge Kommun Västerås Stad Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2020-11-20BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2020-12-01Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 750 +/- 750 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million. No bid may contain Bonds exceeding SEK 750 millio

CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-02BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VASAKRONAN AB: XS1941844174, 2022-02-11 VASAKRONAN AB: XS2051470552, 2024-09-11 HEMSO FASTIGHETS AB: XS1876163103, 2022-03-07 HEMSO FASTIGHETS AB: XS1938445530, 2021-10-22 VOLVO TREASURY AB: XS2153414292, 2022-12-08 VOLVO TREASURY AB: XS2018763461, 2021-06-28 HUSQVARNA AB: SE0009664543, 2022-03-01 HUSQVARNA AB: SE0010869669, 2023-02-14 AB INDUSTRIVARDEN: SE0011869668, 2022-02-28 AB INDUSTRIVARDEN: SE0012676724, 2023-02-20 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2020-11-02Bid date2020-12-02Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1941844174: 30 mln SEK +/-30 mln SEK XS2051470552: 30 mln SEK +/-30 mln SEK XS18761

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-03BondsSTADSHYPOTEK AB: 1590, SE0012676690, 2025-09-03 SWEDBANK HYPOTEK AB: 194, SE0012142206, 2024-09-18 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 Bid date2020-12-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1590: 1200 mln SEK +/-600 mln SEK 194: 1000 mln SEK +/-500 mln SEK 5535: 1000 mln SEK +/-500 mln SEK 580: 800 mln SEK +/-400 mln SEK 518: 600 mln SEK +/-300 mln SEK 2512: 300 mln SEK +/-150 mln SEK 146: 600 mln SEK +/-300 mln SEK Maximum 5500 mln in totalHighest permitted bid volume (corresponding nominal amount)1590: 1200 mln SEK per bid 194: 1000 mln SEK per bid 5535: 1000 mln SEK per bid 580: 800 mln SEK per bid 518: 600 mln SEK per bid 2512: 300 mln SEK per bid 146: 600 mln SEK per bid Lo

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-04BondsSWEDEN I/L BOND: 3108, SE0004211084, 2022-06-01 SWEDEN I/L BOND: 3109, SE0005703550, 2025-06-01 Bid date2020-12-04Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3108: 500 mln SEK +/-250 mln SEK 3109: 500 mln SEK +/-250 mln SEK Maximum 1000 mln in totalHighest permitted bid volume (corresponding nominal amount)3108: 500 mln SEK per bid 3109: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2020-11-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete term

Greenfield cement project in Ethiopia is effective27.11.2020 15:45:28 CETPress release

Company Announcement No. 21 -2020, 3 November 2020 The previously announced signed contract for engineering, procurement and supervision on a cement plant in Ethiopia (Company Announcement No. 1-2019 on 24 January 2019) with Abay Industrial Development Share Company, is now effective. Located near the city of Dejen in Ethiopia, the new greenfield plant will play an important role for the development of local infrastructure. Once fully operational the plant will have a capacity of 5,000 tonnes per day and creating more than 300 new jobs in the area. The contract is valued at around EUR 100 million. The order includes design and engineering, full equipment supply, automation systems, installation and commissioning as well as training and extended supervision. Key deliveries are expected to commence towards the end of 2021. The majority of revenue from this project is expected in the subsequent years. “We are happy to see the contract now in effect,” said Carsten Riisberg Lund, President,